Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

improvement in mean left ventricular ejection fraction (LVEF), a measure of heart function, compared to baseline and relative to the registry group - Patients in the 50 million dose group had a statistically significant absolute improvement in mean 4-month LVEF relative to baseline (9.8 percentage points, representing a 23.4% improvement over baseline, p less than 0.02) - Among patients with more severe heart attacks - as measured by baseline LVEFs less than or equal to 45% - the 50 and 100 million dose groups each demonstrated better than a 25% improvement in mean LVEF at 4 months post treatment over baseline

"Myocardial infarction remains one of the leading causes of death and disability in the United States," said William Hunter, M.D., President and CEO of Angiotech. "We believe these positive Phase 1 results validate the value of our partnership with Athersys, and we are looking forward to working with Athersys to formulate the next clinical development steps for this important product candidate."

Dr. Marc Penn, M.D., Ph.D., co-principal investigator of this study and Director of Cardiovascular Cell Therapy at the Cleveland Clinic, and Director of the Skirball Laboratory for Cardiovascular Cellular Therapeutics, plans to present additional data and results and further discuss the study on September 22, 2010 in Washington, D.C. at the Symposium "Strategies for Cardiovascular Repair: Stem Cell Therapy and Beyond," at the Transvascular Cardiovascular Therapeutics Conference.

"These phase I results suggest that MultiStem is well tolerated when administered to the damaged region of the heart following a heart attack," said Dr. Penn. "Mult
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/17/2014)... 16, 2014 The Activated Carbon ... which is why IBISWorld updated its original industry research ... benefit from an intensified focus on environmental policy. Over ... emission standards for power plants and a range of ... IBISWorld Industry Analyst Sarah Kahn, “a range of downstream ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 22020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ... of the Tom Baker Cancer Centre, Calgary, entitled,"Targeting ... at the American Association for Cancer Research (AACR) ... Diego, California from April,12-16, 2008., The presentation ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will webcast ... 2008 on Monday, April 21, 2008 at 8:30 a.m. ... Executive,Officer, will lead the call. On the same date ... of 2008., The call will be webcast live ...
... Families, EMERYVILLE, Calif., April 15 Alta ... new health care areas designed to,soothe patients and ... offer health resources. The Carol Ann,Read Breast Health ... all in one location, for the quickest turnaround ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting 2Amylin Pharmaceuticals to Webcast First Quarter Results 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... one of the most fundamental processes in the life of ... according to University of Leeds researchers. Arabidopsis thaliana ... cracks in pavements all over Europe and Asia, but the ... rat of the plant world. It has become the ...
... The National Institutes of Health has renewed its ... the Scripps Translational Science Institute (STSI) in the ... years to support innovative research in genomics, wireless ... which is a collaborative program between Scripps Health ...
... In the dog days of summer, female edible dormice ( ... immediately after this energy-intensive period they start to replenish their ... habit seems to give the animals a pleasant taste and ... Romans even kept them in captivity to fatten them up ...
Cached Biology News:Model plant misled scientists about multicellular growth 2Model plant misled scientists about multicellular growth 3NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Fat and fit 2
... The BAS-2500 is ... applications: Molecular Biology (1D ... protein blots, Macroarrays); Pharmacokinetics ... autoradiography, thin layer chromatography); ...
... This microscope is described by end-users ... it incorporates the fundamentals of light microscopy ... and small footprint, it does not require ... in a busy lab environment. The DM-BA300 ...
... BAS-5000 is the highest resolution standard ... top member of Fujifilm's family of ... Imaging Plate (IP) and changeable resolutions ... Fujifilm BAS-5000 does it without compromising ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
Biology Products: